Αρχική World News Data Collection Analysis Demonstrates Changes in Lung Cancer Management Throughout the UK...

Data Collection Analysis Demonstrates Changes in Lung Cancer Management Throughout the UK During the First Wave of the COVID-19 Pandemic

In accordance with guidelines published during the first wave of the COVID-19 pandemic, changes in lung cancer management were made in the UK that most often included altered radiotherapy fractionation, the omission or reduction of chemotherapy, and the provision of radiotherapy in lieu of surgery. These findings were presented at the European Lung Cancer Virtual Congress 2021 (25-27 March) by Kathryn Banfill of the The Christie NHS Foundation Trust, Manchester, UK.

She explained that the COVID-RT Lung study described the changes that were adopted across the UK following the publication of the COVID-19 pandemic guidelines on reduced fractionation for patients with lung cancer treated with curative-intent radiotherapy.1 These guidelines aimed to reduce the number of hospital attendances to limit potential exposure of vulnerable patients to SARS-CoV-2.

COVID-RT Lung is a prospective multicentre UK data collection that includes patients with stage I to III lung cancer (biopsy-proven or diagnosed on cross-sectional imaging) that were referred for and/or treated with radical radiotherapy from 2 April 2020 to 2 October 2020. Every participating centre obtained local approval and anonymised data were collected on a central, cloud-based Research Electronic Data Capture system.

Data collection included patients with a change in disease management as well as those who continued with standard management. The data collected included demographics, COVID-19 diagnosis, diagnostic work-up, radiotherapy and systemic treatment, treatment-related toxicity, and disease/patient status.

Among the 20 UK radiotherapy sites reporting, there were records from 1117 patients with stage I-III lung cancer that were available for analysis on 30 November 2020. Of these, 562 (50%) patients were female with a median age of 72 years (range, 38 to 93) years. COVID-19 had been diagnosed in 15 (1%) patients, with 9 diagnoses occurring prior to radiotherapy.

Changes in management were most often implemented in patients with better ECOG performance status

Due to the pandemic, 160 (14%) patients had their diagnostic investigations affected and 415 (37%) patients had their treatment changed from their centre’s standard of care.

Of the patients with changes in treatment, 210 received a different radiotherapy dose or fractionation and 86 patients were treated with radiotherapy instead of surgery. The patients with a radiotherapy dose/fractionation change received a median of 15 radiotherapy fractions compared to 20 fractions for those who were treated as per standard of care.

Chemotherapy was omitted in 87 patient and reduced in 56 patients. Immunotherapy was omitted or reduced in 6 patients and prophylactic cranial irradiation was omitted in 4 patients. A watch and wait regimen was instituted for 24 patients and 3 patients received no treatment.

Dr. Banfill and co-investigators determined that patients with ECOG performance status (PS) 0-1 were more likely to have their treatment changed compared to patients with a poorer PS.


Changes in management in COVID-RT Lung study were most often implemented in patients with better ECOG performance status.

© Kathryn Banfill.


The authors concluded that data from this nationwide cohort shows that clinicians in the UK changed the management of patients with stage I-III lung cancer in line with national COVID-19 guidelines.

They noted that the primary changes were a reduction in chemotherapy use and an increase in radiotherapy hypofractionation. The data collection for COVID-RT Lung is ongoing including data on outcomes of patients treated during the pandemic. This will help to determine the effect of these changes on cancer recurrence and patients’ survival.

This study was funded by the Biomedical Research Centre, Manchester.


  1. Faivre-Finn C, Fenwick JD, Franks KN, et al. Guidelines Reduced Fractionation in Lung Cancer Patients Treated with Curative intent Radiotherapy during the COVID-19 Pandemic. Clinical Oncology 2020;32:481-489. DOI: https://doi.org/10.1016/j.clon.2020.05.001


203MO – Banfill K, Price G, Wicks K, et al. Changes in management for patients with lung cancer treated with radical radiotherapy during the first wave of the COVID-19 pandemic in the UK (COVID-RT Lung). European Lung Cancer Virtual Congress 2021 (25-27 March).



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

De qué manera el seguimiento de los síntomas mejora la atención oncológica

Se sabe bien que el tratamiento contra el cáncer genera efectos secundarios significativos. Por ejemplo, la quimioterapia puede causar caída del cabello, náuseas e...

Apalutamide Plus ADT Provides Significant Improvement in Overal Survival and Delays Onset of Progression in mCSPC

The final analysis of the TITAN demonstrates that the long-term use of apalutamide plus androgen deprivation therapy (ADT) provided significant improvement in overall survival...

Man Who Lost His Mother to Breast Cancer Opens Resource Center in Her Memory

After the death of a beloved parent, you can find yourself wanting to carry their legacy forward in their absence. One man in Ohio...

Navigating Cancer Survivorship as a Transgender or Non-Binary Person

Mal Malme (Mal or they/them) is a proud Boston-based theater artist, activist, writer, and health care clown. Mal is co-founder of Queer Soup Theater...

Sing Anyway

“Some days there won’t be a song in your heart. Sing anyway.” – Emory Austin I love this thought from Emory Austin. I am reminded...

Topotecan–Berzosertib Combination Shows Promise against Small Cell Lung Cancer

May 5, 2021, by NCI Staff A small clinical trial tested the combination of topotecan with the drug berzosertib, which inhibits a protein that helps repair...